Claudin-4 differentiates biliary tract cancers from hepatocellular carcinomas

Modern Pathology

Volumn 19, Issue 3, 2006, Pages 460-469

  Lódi, Csaba ^a   Szabó, Erzsébet ^a   Holczbauer, Agnes ^a   Batmunkh, Enkhjargal ^a   Szíjártó, Attila ^a   Kupcsulik, Péter ^a   Kovalszky, Ilona ^a   Paku, Sándor ^a   Illyés, György ^a   Kiss, András ^a   Schaff, Zsuzsa ^a  

^a SEMMELWEIS UNIVERSITY   (Hungary)

Author keywords

Biliary tract cancer; Claudin 4; Hepatocellular carcinoma; Liver; Tight junction

Indexed keywords

CLAUDIN 4; CYTOKERATIN 19; CYTOKERATIN 7;

ANTIBODY LABELING; ARTICLE; BILIARY TRACT CANCER; CONTROLLED STUDY; CORRELATION ANALYSIS; GALLBLADDER CANCER; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER CELL; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STATISTICAL SIGNIFICANCE; TISSUE MICROARRAY; TUMOR CELL; WESTERN BLOTTING;

ADENOCARCINOMA; BILIARY TRACT NEOPLASMS; BLOTTING, WESTERN; CARCINOMA, HEPATOCELLULAR; DIAGNOSIS, DIFFERENTIAL; GENE EXPRESSION; HUMANS; IMMUNOHISTOCHEMISTRY; KERATIN-7; KERATINS; LAMININ; LIVER; LIVER NEOPLASMS; MEMBRANE PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TISSUE ARRAY ANALYSIS;

EID: 33244465342     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.3800549     Document Type: Article

References (45)

1. El-Serag HB, Davila JA, Petersen NJ, et al. The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update. Ann Intern Med 2003;139:817-823.
2. Davila JA, El-Serag HB. Cholangiocarcinoma: the 'other' liver cancer on the rise. Am J Gastroenterol 2002;97:3199-3200.
3. Maeda T, Adachi E, Kajiyama K, et al. Combined hepatocellular and cholangiocarcinoma: proposed criteria according to cytokeratin expression and analysis of clinicopathologic features. Hum Pathol 1995;26:956-964.
4. Itamoto T, Asahara T, Katayama K, et al. Double cancer - hepatocellular carcinoma and intrahepatic cholangiocarcinoma with a spindle-cell variant. J Hepatobiliary Pancreat Surg 1999;6:422-426.
5. Harada K, Masuda S, Hirano M, et al. Reduced expression of syndecan-1 correlates with histologic dedifferentiation, lymph node metastasis, and poor prognosis in intrahepatic cholangiocarcinoma. Hum Pathol 2003;34:857-863.
6. Shibahara H, Tamada S, Higashi M, et al. MUC4 is a novel prognostic factor of intrahepatic cholangiocarcinoma-mass forming type. Hepatology 2004;39:220-229.
7. Sugimachi K, Taguchi K, Aishima S, et al. Altered expression of beta-catenin without genetic mutation in intrahepatic cholangiocarcinoma. Mod Pathol 2001;14:900-905.
8. Cabibi D, Licata A, Barresi E, et al. Expression of cytokeratin 7 and 20 in pathological conditions of the bile tract. Pathol Res Pract 2003;199:65-70.
9. Aishima S, Asayama Y, Taguchi K, et al. The utility of keratin 903 as a new prognostic marker in mass-forming-type intrahepatic cholangiocarcinoma. Mod Pathol 2002;15:1181-1190.
10. Minervini MI, Demetris AJ, Lee RG, et al. Utilization of hepatocyte-specific antibody in the immunocytochemical evaluation of liver tumors. Mod Pathol 1997;10:686-692.
11. Tsukita S, Furuse M, Itoh M. Multifunctional strands in tight junctions. Nat Rev Mol Cell Biol 2001;2:285-293.
12. Johnson LG. Applications of imaging techniques to studies of epithelial tight junctions. Adv Drug Deliv Rev 2005;57:111-121.
13. Hadj-Rabia S, Baala L, Vabres P, et al. Claudin-1 gene mutations in neonatal sclerosing cholangitis associated with ichthyosis: a tight junction disease. Gastroenterology 2004;127:1386-1390.
14. Heiskala M, Peterson PA, Yang Y. The roles of claudin superfamily proteins in paracellular transport. Traffic 2001;2:93-98.
15. Morita K, Furuse M, Fujimoto K, et al. Claudin multigene family encoding four-transmembrane domain protein components of tight junction strands. Proc Natl Acad Sci USA 1999;96:511-516.
16. Turksen K, Troy TC. Barriers built on claudins. J Cell Sci 2004;117:2435-2447.
17. Soini Y. Expression of claudins 1, 2, 3, 4, 5 and 7 in various types of tumours. Histopathology 2005;46:551.
18. Katahira J, Inoue N, Horiguchi Y, et al. Molecular cloning and functional characterization of the receptor for Clostridium perfringens enterotoxin. J Cell Biol 1997;136:1239-1247.
19. Kominsky SL, Vali M, Korz D, et al. Clostridium perfringens enterotoxin elicits rapid and specific cytolysis of breast carcinoma cells mediated through tight junction proteins claudin 3 and 4. Am J Pathol 2004;164:1627.
20. Long H, Crean CD, Lee WH, et al. Expression of Clostridium perfringens enterotoxin receptors claudin-3 and claudin-4 in prostate cancer epithelium. Cancer Res 2001;61:7878-7881.
21. Michl P, Buchholz M, Rolke M, et al. Claudin-4: a new target for pancreatic cancer treatment using Clostridium perfringens enterotoxin. Gastroenterology 2001;121:678-684.
22. Nichols LS, Ashfaq R, Iacobuzio-Donahue CA. Claudin 4 protein expression in primary and metastatic pancreatic cancer: support for use as a therapeutic target. Am J Clin Pathol 2004;121:226-230.
23. McClane BA, McDonel JL. The effects of Clostridium perfringens enterotoxin on morphology, viability, and macromolecular synthesis in Vero cells. J Cell Physiol 1979;99:191-200.
24. Pfaffl MW, Horgan GW, Dempfle L. Relative expression software tool (REST) for group-wise comparison and statistical analysis of relative expression results in real-time PCR. Nucl Acid Res 2002;30:e36.
25. Gonzalez-Mariscal L, Betanzos A, Nava P, et al. Tight junction proteins. Prog Biophys Mol Biol 2003;81:1-44.
26. Sobel G, Páska C, Szabó I, et al. Increased expression of claudins in cervical squamous intraepithelial neoplasia and invasive carcinoma. Hum Pathol 2005;36:162-169.
27. Van Itallie C, Rahner C, Anderson JM. Regulated expression of claudin-4 decreases paracellular conductance through a selective decrease in sodium permeability. J Clin Invest 2001;107:1319-1327.
28. Tsukahara M, Nagai H, Kamiakito T, et al. Distinct expression patterns of claudin-1 and claudin-4 in intraductal papillarymucinous tumors of the pancreas. Pathol Int 2005;55:63.
29. Hibbs K, Skubitz KM, Pambuccian SE, et al. Differential gene expression in ovarian carcinoma: identification of potential biomarkers. Am J Pathol 2004;165:397-414.
30. Fausto N, Campbell JS. The role of hepatocytes and oval cells in liver regeneration and repopulation. Mech Develop 2003;120:117-130.
31. Roskams T, Yang SQ, Koteish A, et al. Oxidative stress and oval cell accumulation in mice and humans with alcoholic and nonalcoholic fatty liver disease. Am J Pathol 2003;163:1301-1311.
32. Paku S, Schnur J, Nagy P, et al. Origin and structural evolution of the early proliferating oval cells in rat liver. Am J Pathol 2001;158:1313-1323.
33. Sell S. Is there a liver stem cell? Cancer Res 1990;50:3811-3815.
34. Shiojiri N, Lemire JM, Fausto N. Cell lineages and oval cell progenitors in rat liver development. Cancer Res 1991;51:2611-2620.
35. Evarts RP, Nagy P, Marsden E, et al. A precursor-product relationship exists between oval cells and hepatocytes in rat liver. Carcinogenesis 1987;8:1737-1740.
36. Lenzi R, Liu MH, Tarsetti F, et al. Histogenesis of bile duct-like cells proliferating during ethionine hepatocarcinogenesis. Evidence for a biliary epithelial nature of oval cells. Lab Invest 1992;66:390-402.
37. Kramer F, White K, Kubbies M, et al. Genomic organization of claudin-1 and its assessment in hereditary and sporadic breast cancer. Hum Genet 2000;107:249-256.
38. Miwa N, Furuse M, Tsukita S, et al. Involvement of claudin-1 in the beta-catenin/Tcf signaling pathway and its frequent upregulation in human colorectal cancers. Oncol Res 2000;12:469-476.
39. Resnick MB, Konkin T, Routhier J, et al. Claudin-1 is a strong prognostic indicator in stage II colonic cancer: a tissue microarray study. Mod Pathol 2005;18:511-518.
40. Heinzelmann-Schwarz VA, Gardiner-Garden M, Henshall SM, et al. Overexpression of the cell adhesion molecules DDR1, Claudin 3, and Ep-CAM in metaplastic ovarian epithelium and ovarian cancer. Clin Cancer Res 2004;10:4427-4436.
41. Kominsky SL, Argani P, Korz D, et al. Loss of the tight junction protein claudin-7 correlates with histological grade in both ductal carcinoma in situ and invasive ductal carcinoma of the breast. Oncogene 2003;22: 2021-2033.
42. Offner S, Hekele A, Teichmann U, et al. Epithelial tight junction proteins as potential antibody targets for pancarcinoma therapy. Cancer Immunol Immunother 2005;54:431-445.
43. Moll R, Franke WW, Schiller DL, et al. The catalog of human cytokeratins: patterns of expression in normal epithelia, tumors and cultured cells. Cell 1982;31:11-24.
44. Porcell AI, De Young BR, Proca DM, et al. Immunohistochemical analysis of hepatocellular and adenocarcinoma in the liver: MOC31 compares favorably with other putative markers. Mod Pathol 2000;13:773-778.
45. Lau SK, Prakash S, Geller SA, et al. Comparative immunohistochemical profile of hepatocellular carcinoma, cholangiocarcinoma, and metastatic adenocarcinoma. Hum Pathol 2002;33:1175-1181.